This story is from the CurrentWire archive. Coverage details reflect the last time it was updated.
LEO Pharma Inc. (Canada) Finalizes Letter of Intent with pCPA for Anzupgo® (delgocitinib cream) for Chronic Hand Eczema
BALLERUP, Denmark — ANZUPGO (delgocitinib cream) has taken a major step towards public reimbursement in Canada following the successful conclusion of negotiations between pan-Canadian Pharmaceutical Alliance (pCPA) and LEO Pharma Canada. This marks important progress toward access for adults with moderate to severe chronic hand eczema (CHE) whose disease is inadequately controlled with, or for […]
Financial Post
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
In this story
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on . CurrentWire published this page 15 minutes later, on .
Filed under Business · Canada · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: Canada (36), Pharma Inc (none), Canada Finalizes Letter (none), Chronic Hand Eczema (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.